Medicines Price Cap: Government Lowers Costs of 30 Essential Formulations for Diabetes and Heart Patients

Following a landmark medicines price cap issued by the National Pharmaceutical Pricing Authority (NPPA), the retail rates of 30 essential drug formulations have been slashed to provide major relief for chronic patients nationwide

Kolhapur | 02 June 2026: The National Pharmaceutical Pricing Authority (NPPA) has issued an official order capping the retail prices of 30 essential drug formulations. This decisive move, regulated under the Drugs (Prices Control) Order 2013 (DPCO), directly targets escalating healthcare costs. The revision applies to widely used therapies managing chronic conditions, including diabetes, cardiovascular diseases, allergies, vitamin deficiencies, and organ transplant care, making vital treatments significantly more affordable for common citizens.

According to the notification issued by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers, the price caps cover several high-demand combinations. The retail price for Vitamin D-3 oral solution has been fixed at ₹14.91 per ml, while a combination of Atorvastatin and Fenofibrate, used to manage cholesterol levels, is capped at ₹18.46 per tablet. For heart and hypertension patients, the Bisoprolol Fumarate and Amlodipine combination will now cost ₹9.40 per tablet.

Significant relief has also been extended to diabetes patients, with the retail price for the Empagliflozin, Sitagliptin, and Metformin Extended-Release combination set at ₹14.88 per tablet. Notably, for organ transplant recipients, the price of Tacrolimus Prolonged-Release (3 mg) capsules has been capped at ₹127 per capsule. The NPPA stated that these fixed rates exclude Goods and Services Tax (GST), which can only be charged additionally if actually paid by the manufacturing companies.

Pharmaceutical companies and marketing agencies are legally mandated to implement these updated rates immediately and update their pricing logs on the Integrated Pharmaceutical Database Management System (IPDMS). Furthermore, retailers and distributors must prominently display these revised price lists for consumers. The NPPA warned that any manufacturer or marketer found overcharging consumers will face stringent legal action, including the recovery of the excess amount along with added interest.

Social media Handles :
Instagram
Youtube
Facebook
Twitter

Also Read- Pune